Pro-Pharmaceuticals: Announcement on Obtaining a Notice of Approval for Clinical Trials of Drugs
Pro-Pharmaceuticals: Announcement on Obtaining a Notice of Approval of the Application for the Marketing of Chemical Ingredients
Prologis Pharmaceutical: 2024-58. Announcement on signing a strategic cooperation framework agreement
Pro-Pharmaceuticals: Announcement on Obtaining a Notice of Approval of the Application for the Marketing of Chemical Ingredients
Pro-Pharmaceuticals: Notice on Obtaining a Notice of Approval for Drug Supplementary Applications
Pro-Pharmaceuticals: Announcement on Obtaining a Notice of Approval of the Application for the Marketing of Chemical Ingredients
Pro-Pharmaceuticals: Notice on Obtaining a Notice of Approval for Drug Supplementary Applications
Prologis Pharmaceuticals: Announcement on the signing of a strategic cooperation framework agreement
Prologis Pharmaceutical: Announcement on foreign investment of subsidiary companies
Apeloa Pharmaceutical: Summary table of non-operating funds utilization and other related funds flow for the first half of the year.
Apeloa Pharmaceutical: Financial Report for the first half of 2024.
Apeloa Pharmaceutical: Announcement Regarding the Approval by the USA FDA for Products of our wholly-owned Subsidiary.
Prologis Pharmaceutical: Announcement on Cancelling Repurchase Shares, Reducing Registered Capital and Notifying Creditors
Prologis Pharmaceuticals: Legal Opinion of the 2023 Annual General Meeting of Shareholders
Pro-Pharmaceuticals: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Prologis Pharmaceuticals: Announcement on the signing of a strategic cooperation framework agreement
Prologis Pharmaceutical: Announcement on the extension of the term of the company's first employee stock ownership plan
Prologis Pharmaceuticals: Board of Directors Remuneration and Assessment Committee Rules (2024 Revision)
Pro-Pharmaceuticals: Special Meeting System for Independent Directors (established in 2024)
Prologis Pharmaceuticals: Amendments to the Articles of Association
No Data